GRAIL, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Ragusa
- Full Time Employees
- 1,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 1525 O’Brien Drive Menlo Park CA United States of America 94025
- IPO Date
- Jun 12, 2024
- CIK
- 0001699031
- Website
- grail.com
- Similar Companies
- Business
- GRAIL, Inc. is a biotechnology company headquartered in Menlo Park, California, founded in 2015, specializing in early cancer detection through advanced biotechnology and genomics. The company develops and commercializes the Galleri test, a multi-cancer early detection (MCED) blood test designed to screen for multiple types of cancer at early, asymptomatic stages using targeted methylation-based next-generation sequencing technologies combined with machine learning and automation. GRAIL's core offerings include multi-cancer early detection assays, tests for risk stratification, minimal residual disease detection, biomarker subtyping, and tools for treatment and recurrence monitoring. Its technologies aim to support the continuum of care in oncology from screening to precision medicine. GRAIL operates primarily in the United States, with additional locations in Washington, D.C., North Carolina, and the United Kingdom, serving a global healthcare market including symptomatic and asymptomatic patients. In recent years, GRAIL completed its spin-off from Illumina in June 2024 following regulatory mandates by European authorities, thereby transitioning into an independent publicly traded company (Ticker: GRAL). The separation marked a major strategic shift as Illumina had previously acquired GRAIL in 2021 but was required to divest due to antitrust concerns. Since becoming independent, GRAIL has expanded commercial sales of its Galleri test, reporting a 39% year-over-year increase in test volume and reaching $32.6 million in revenue in the third quarter of 2025. The company also announced ongoing pivotal registrational studies with plans to read out results in 2025 and 2026 supporting FDA submission and adoption. Strategic partnerships, such as a collaboration with athenahealth, aim to streamline ordering and integrate Galleri testing into broader healthcare provider workflows. GRAIL continues to focus on operational efficiencies, business growth, and market penetration in multi-cancer early detection, reinforced by recent data demonstrating improved test accuracy and expanding clinical validation efforts. GRAIL's business is positioned at the intersection of biotechnology, oncology diagnostics, and precision medicine within the broader healthcare industry. Its primary customer base includes healthcare providers, oncologists, and health systems engaged in cancer screening and early detection. Key products include the Galleri multi-cancer early detection blood test, supported by proprietary sequencing and analytic platforms that harness population-scale clinical data and AI-driven interpretation. The company targets markets in the United States and internationally, with a strong emphasis on regulatory clearance, clinical utility demonstration, and adoption within preventive health and oncology care pathways. GRAIL maintains a commitment to innovation in early cancer detection technology while addressing challenges in the evolving landscape of liquid biopsy diagnostics. Overall, GRAIL represents a leading innovator in early-stage cancer screening and precision oncology diagnostics, building on foundational genomic sequencing technologies and strategic pivots to independence and commercial expansion in the competitive biotech sector focused on cancer mortality reduction. Recent developments underline the company's transition to a growth-oriented, standalone entity with increasing commercial traction and regulatory milestones anticipated in the near term.
GRAIL, Inc. (GRAL) Shareholder/Analyst Call Transcript
Why Grail Shares Crashed Today
Stocks Mixed as Oil, Iran Tensions Overshadow Chip Rally
GRAIL's Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Grail's Slump Enters Week 10. Is There Any End in Sight?
GRAIL to Present at the 2026 Jefferies Global Healthcare Conference
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
GRAIL Reports First Quarter 2026 Financial Results
GRAIL to Present at the BofA Securities 2026 Health Care Conference
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
GRAIL to Announce First Quarter 2026 Financial Results